208 related articles for article (PubMed ID: 27548656)
1. Recently discovered EZH2 and EHMT2 (G9a) inhibitors.
Soumyanarayanan U; Dymock BW
Future Med Chem; 2016 Sep; 8(13):1635-54. PubMed ID: 27548656
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas.
Wu D; Zeng X; Zhao Y; Qin M; Gong P
Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
[TBL] [Abstract][Full Text] [Related]
3. H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.
Rogawski DS; Grembecka J; Cierpicki T
Future Med Chem; 2016 Sep; 8(13):1589-607. PubMed ID: 27548565
[TBL] [Abstract][Full Text] [Related]
4. Tazemetostat: First Approval.
Hoy SM
Drugs; 2020 Apr; 80(5):513-521. PubMed ID: 32166598
[TBL] [Abstract][Full Text] [Related]
5. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Dockerill M; Gregson C; O' Donovan DH
Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
[TBL] [Abstract][Full Text] [Related]
6. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
[TBL] [Abstract][Full Text] [Related]
7. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
Zhou B; Liang X; Mei H; Qi S; Jiang Z; Wang A; Zou F; Liu Q; Liu J; Wang W; Hu C; Chen Y; Wang Z; Wang B; Wang L; Liu J; Liu Q
J Med Chem; 2021 Oct; 64(20):15170-15188. PubMed ID: 34664960
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.
Baker T; Nerle S; Pritchard J; Zhao B; Rivera VM; Garner A; Gonzalvez F
Oncotarget; 2015 Oct; 6(32):32646-55. PubMed ID: 26360609
[TBL] [Abstract][Full Text] [Related]
9. 2,2- dimethylbenzopyran derivatives containing pyridone structural fragments as selective dual-targeting inhibitors of HIF-1α and EZH2 for the treatment of lung cancer.
Xu H; Zhang J; Zhuang J; Chen Y; Chen L; Wang J; Cao R; Liu F; Wang K; Zhang X; Wang L; Chen G
Bioorg Chem; 2024 Jun; 147():107419. PubMed ID: 38703440
[TBL] [Abstract][Full Text] [Related]
10. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Dual Lysine Methyltransferase G9a and EZH2 Inhibitors with In Vivo Efficacy against Malignant Rhabdoid Tumor.
Shi Y; Zhang Q; Zhang M; Chen Y; Sun J; Chen L; Liu S; Liu Z; Yang J; Wu C; Zheng Z; Wang L; Chen G
J Med Chem; 2023 Apr; 66(8):5685-5702. PubMed ID: 37021456
[TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.
Kung PP; Rui E; Bergqvist S; Bingham P; Braganza J; Collins M; Cui M; Diehl W; Dinh D; Fan C; Fantin VR; Gukasyan HJ; Hu W; Huang B; Kephart S; Krivacic C; Kumpf RA; Li G; Maegley KA; McAlpine I; Nguyen L; Ninkovic S; Ornelas M; Ryskin M; Scales S; Sutton S; Tatlock J; Verhelle D; Wang F; Wells P; Wythes M; Yamazaki S; Yip B; Yu X; Zehnder L; Zhang WG; Rollins RA; Edwards M
J Med Chem; 2016 Sep; 59(18):8306-25. PubMed ID: 27512831
[TBL] [Abstract][Full Text] [Related]
13. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
Lue JK; Amengual JE
Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
[TBL] [Abstract][Full Text] [Related]
14. Insights for the design of protein lysine methyltransferase G9a inhibitors.
Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
[TBL] [Abstract][Full Text] [Related]
15. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
Cao H; Li L; Yang D; Zeng L; Yewei X; Yu B; Liao G; Chen J
Eur J Med Chem; 2019 Oct; 179():537-546. PubMed ID: 31276898
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.
Katayama K; Ishii K; Tsuda E; Yotsumoto K; Hiramoto K; Suzuki M; Yasumatsu I; Igarashi W; Torihata M; Ishiyama T; Katagiri T
Bioorg Med Chem Lett; 2020 Oct; 30(20):127475. PubMed ID: 32781218
[TBL] [Abstract][Full Text] [Related]
18. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
19. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]